Patent · US Active

(Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases

US9486435B2 · kind B2 · utility

7Cited by
22References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 30, 2014
Grant dateNov 8, 2016
Priority date—
Expiry dateDec 30, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07C2601/16
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.